Evidence map›Paper›PMID 26283340›Full record

ArticleInfection and immunity2015

Simultaneous Host-Pathogen Transcriptome Analysis during Granulibacter bethesdensis Infection of Neutrophils from Healthy Subjects and Patients with Chronic Granulomatous Disease.

David E Greenberg, Daniel E Sturdevant, Kimberly R Marshall-Batty, Jessica Chu, Anthony M Pettinato, Kimmo Virtaneva, John Lane, Bruce L Geller, Stephen F Porcella, John I Gallin and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. International journal of molecular sciences · 2021
    Article
  3. Immune Subtyping in Latent Tuberculosis.Frontiers in immunology · 2021
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

David E GreenbergLaboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA Departments of Medicine and Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Daniel E SturdevantGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, USA.
Kimberly R Marshall-BattyLaboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA Departments of Medicine and Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Jessica ChuLaboratory of Host Defenses, NIAID, NIH, Bethesda, Maryland, USA.
Anthony M PettinatoLaboratory of Host Defenses, NIAID, NIH, Bethesda, Maryland, USA.
Kimmo VirtanevaGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, USA.
John LaneGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, USA.
Bruce L GellerDepartment of Microbiology, Oregon State University, Corvallis, Oregon, USA.
Stephen F PorcellaGenomics Unit, Research Technologies Branch, Rocky Mountain Laboratories, NIAID, NIH, Hamilton, Montana, USA.
John I GallinLaboratory of Host Defenses, NIAID, NIH, Bethesda, Maryland, USA.
Steven M HollandLaboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, Maryland, USA.
Kol A ZaremberLaboratory of Host Defenses, NIAID, NIH, Bethesda, Maryland, USA kzarember@niaid.nih.gov.
National Institutes of Health · USThe University of Texas Southwestern Medical Center · USNational Institute of Allergy and Infectious Diseases · USOregon State University · US

Funding

Infectious Diseases Research Technologies Core - RMLZICAI001052 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$133.3M
Genes And Gene Products As ImmunoadjuvantsZIAAI000647 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.6M
Transgenic Animal Models Of Human Immune DefectsZIAAI000646 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI HOLLAND, STEVEN · 2009 to 2025
$22.2M
Clinical Studies Of Abnormal Host DefenseZIAAI000155 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALLIN, JOHN I · 2009 to 2022
$3.1M
Laboratory Studies of Abnormal Host Defense and Immunoregulatory DiseasesZIAAI001151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZAREMBER, KOL · 2011 to 2022
$2.4M
Intramural NIH HHS
6 · The paper itself

Abstract

Polymorphonuclear leukocytes (PMN) from patients with chronic granulomatous disease (CGD) fail to produce microbicidal concentrations of reactive oxygen species (ROS) due to mutations in NOX2. Patients with CGD suffer from severe, life-threatening infections and inflammatory complications. Granulibacter bethesdensis is an emerging Gram-negative pathogen in CGD that resists killing by PMN of CGD patients (CGD PMN) and inhibits PMN apoptosis through unknown mechanisms. Microarray analysis was used to study mRNA expression in PMN from healthy subjects (normal PMN) and CGD PMN during incubation with G. bethesdensis and, simultaneously, in G. bethesdensis with normal and CGD PMN. We detected upregulation of antiapoptotic genes (e.g., XIAP and GADD45B) and downregulation of proapoptotic genes (e.g., CASP8 and APAF1) in infected PMN. Transcript and protein levels of inflammation- and immunity-related genes were also altered. Upon interaction with PMN, G. bethesdensis altered the expression of ROS resistance genes in the presence of normal but not CGD PMN. Levels of bacterial stress response genes, including the ClpB gene, increased during phagocytosis by both normal and CGD PMN demonstrating responses to oxygen-independent PMN antimicrobial systems. Antisense knockdown demonstrated that ClpB is dispensable for extracellular growth but is essential for bacterial resistance to both normal and CGD PMN. Metabolic adaptation of Granulibacter growth in PMN included the upregulation of pyruvate dehydrogenase. Pharmacological inhibition of pyruvate dehydrogenase by triphenylbismuthdichloride was lethal to Granulibacter. This study expands knowledge of microbial pathogenesis of Granulibacter in cells from permissive (CGD) and nonpermissive (normal) hosts and identifies potentially druggable microbial factors, such as pyruvate dehydrogenase and ClpB, to help combat this antibiotic-resistant pathogen.

Indexed as

AcetobacteraceaeAdultAgedBacterial ProteinsFemaleGene Expression ProfilingGranulomatous Disease, ChronicHealthy VolunteersHost-Pathogen InteractionsHumansMaleMiddle AgedNeutrophilsPhagocytosisYoung AdultBacterial Proteins

Identifiers

PMID26283340
PMCPMC4598409
OpenAlexW2193963146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.